To include your compound in the COVID-19 Resource Center, submit it here.

Exelixis eyeing 2021 combo submission in prostate cancer following new readout

Exelixis believes newly released initial data from a Phase Ib trial cohort to treat prostate cancer could augur future results from the same twice-expanded cohort that could support a regulatory submission of cabozantinib plus Tecentriq as soon as next year.

Approval for second-line or later patients with metastatic castration-resistant prostate cancer (mCRPC) would offer a new

Read the full 559 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE